Диссертация (1140240), страница 17
Текст из файла (страница 17)
J. Dermatol. 2010; 163(1): 188—192. doi: 10.1111/j.13652133.2010.09778.107.Lecha M. Use of UVB in vitiligo. //Basic and Clinical Dermatology.2004; 29: 341—347108.Leone G., Iacovelli P., Paro Vidolin A., Picardo M. Monochromaticexcimer light 308 nm in the treatment of vitiligo: a pilot study // J. Eur. Acad.Dermatol. Venereol. 2003. -V.17, n.5. - P.
531-537.109.Li K., Li C., Gao L., Yang L., Li M., Liu L., Zhang Z., Liu Y., Gao T.A functional single-nucleotide polymorphism in the catechol-O-methyltransferasegene alter vitiligo risk in a Chinese population.// Arch Dermatol Res. 2009Oct;301(9):681-7.110.Li Q., Lv Y., Li C., Yi X., Long H.A., Qiao H., Lu T., Luan Q., Li K.,Wang X., Wang G., Gao T. Vitiligo autoantigen VIT75 is identified as lamin A invitiligo by serological proteome analysis based on mass spectrometry.// J InvestDermatol. 2011 Mar;131(3):727-34. doi: 10.1038/jid.2010.341.111.Liu L., Li C., Gao J., Li K., Zhang R., Wang G., Li C., Gao T.Promoter variant in the catalase gene is associated with vitiligo in Chinesepeople.//JInvestDermatol.2010Nov;130(11):2647-53.doi:10.1038/jid.2010.192. Epub 2010 Jul 8.109112.Lorincz A.
L. Disturbance of melanin pigmentation // J. Invest.Dermatol. 1959. -Vol. 32, N 2. -P. 223-227113.Lotti T., Gori A., Zanieri F. et al. Vitiligo: new and emergingtreatments // Dermatol. Ther. – 2008. - Vol. 21. – P. 110-117.114.Mahmoud F., Abul H., Haines D., Al-Saleh C., Khajeji M., Whaley K.Decreased total numbers of peripheral blood lymphocytes with elevatedpercentages of CD4+CD45RO+ and CD4+CD25+ of T-helper cells in nonsegmental vitiligo. // J Dermatol.
2002 Feb; 29(2): 68-73.115.Manolache L., Dumetrescu R., Benea V. Similarities in somepsychomatic aspects in alopecia areata and vitiligo patients.// JEADV, 2004, vol18; 186-18116.Marcus D.K., Gurley J.R., Marchi M.M., Bauer C. Cognitive andperceptual variables in hypochondriasis and health anxiety: a systematic review.//Clin Psychol Rev.
2007 Mar;27(2):127-39. Epub 2006 Nov 3.117.Marek L., Oglodek E., Placek W., Araszkiewicz A. Coexistence ofvitiligo and psychiatric disorders.//JEADV-2008-FP1495118.McNeely W., Goa K.L. 5-methoxypsoralen: a review of its effects inpsoriasis and vitiligo.// Drugs, 1998, 56:667690.119.Menchini G., Tsoureli-Nikita E., Hercogova J. Narrow-band UV-Bmicrophototherapy: a new treatment of vitiligo.// J.
Eur. Acad. Dermatol.Venereol. 2003; 17: 171—177120.Moellmann G., Klein-Angerer S., Scollay D.A., Nordlund J.J., LernerA.B. Extracellular granular material and degeneration of keratinocytes in thenormally pigmented epidermis of patients with vitiligo.// J Invest Dermatol. 1982Nov;79(5):321-30.121.Mori M., Campolmi P., Mavilia L., Rossi R., Cappugi P., PimpinelliN.
Monochromatic excimer light (308 nm) in patch-stage IA mycosis fungoides. //J. Am. Acad. Dermatol. 2004; 50 (6): 943—945.122.Morelli J.G., Norris D.A. Influence of inflammatory mediators andcytokines on human melanocyte function // J. Invest. Dermatol. – 1993. – Vol. 100.110– P. 191-195.123.NamaziM.R.Neurogenicdysregulation,oxidativestress,autoimmunity, and melanocytorrhagy in vitiligo: can they be interconnected?//Pigment Cell Res.
2007 Oct;20(5):360-3.124.Naughton G.K., Eisinger M., Bystryn J.C. Antibodies to normalhuman melanocytes in vitiligo.// J Exp Med. 1983 Jul 1;158(1):246-51.125.Nicolaidou E., Antoniou C., Stratigos A., Katsambas A.D.Narrowband ultraviolet B phototherapy and 308 nm eximer laser in the treatmentof vitiligo: a review.// J. Am. Acad. Dermatol. 2009. - V.60. - P.470-7. doi:10.1016/j.jaad.2008.07.053.126.Njoo M.D., Bos J.D., Westerhof W.
Treatment of generalized vitiligoin children with narrow-band (TL-01) UVB radiation therapy. // J. Am. Acad.Dermatol. 2000; 42(2): 245—253127.Njoo M.D., Westerhof W. Vitiligo: pathogenesis and treatment. Am. JClin Dermatol. 2001; 2(3): 167—181.128.Nordlund J.J. Vitiligo: a review of some facts lesser known aboutdepigmentation // Indian J. Dermatol.
– 2011. – Vol. 56, N 2. – P. 180-189.129.Oiso N., Iba Y., Kawara S., Kawada A. Halo phenomenon inneurofibromas and generalized vitiligo in a patient with neurofibromatosis type 1.// Clin Exp Dermatol. 2007 Mar;32(2):207-8.130.Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect ofvitiligo on self-reported health-related quality of life.Br J Dermatol.
2005Jun;152(6):1165-72131.Ostovari N., Passeran T., Zacaria W., Fontas E., Larouy J.C., BlotJ.F., Lacour J.P., Ortonne J.P. Treatment of vitiligo by 308 nm eximer laser: anevaluation of variables affecting treatment response // Laser Surg. Med. 2004. V.35, n.2. - P. 125-156.132.Oyarbide-Valencia K., van den Boorn J.G., Denman C.J., Li M.,Carlson J.M., Hernandez C., Nishimura M.I., Das P.K., Luiten R.M., Le Poole I.C.Therapeutic implications of autoimmune vitiligo T cells.// Autoimmun Rev. 2006111Aug; 5(7):486-92.
Epub 2006 May 6.133.Palermo B., Campanelli R., Garbelli S., Mantovani S., Lantelme E.,Brazzelli V., Ardigó M., Borroni G., Martinetti M., Badulli C., Necker A.,Giachino C. Specific cytotoxic T lymphocyte responses against Melan-A/MART1,tyrosinase and gp100 in vitiligo by the use of major histocompatibilitycomplex/peptide tetramers: the role of cellular immunity in the etiopathogenesis ofvitiligo.// J Invest Dermatol.
2001 Aug;117(2):326-32.134.Park Y. K., Kim N. S., Harm S. K. et al. Identification of autoantibodyto melanocytes and characterization of vitiligo-antigen in Vitiligo patients // J.Dermatol. Sei.- 1996. -Vol. 11, N2. P. 111-120135.Parsad D., Dogra S., Kanwar A.J. Quality of life in patients withvitiligo.
Health Quality Life Outcomes.2003; 1: 58.doi: 10.1186/1477-7525-1-58.136.Passeron T., Ortonne J.P. Physiopathology and genetics of vitiligo.//JAutoimmun. 2005;25 Suppl:63-8.Epub 2005 Nov 18.137.Passeron T., Ortonne P.M. The 308 nm eximer laser in dermatology//Presse Med, 2005; 26, 43 (4): 301 309.138.Prignano F., Ricceri F., Bianchi B. et al. Dendritic cells: ultrastructuraland immunophenotypical changes upon nb-UVB in vitiligo skin // Arch. Dermatol.Res. – 2011.
– Vol. 303, N. 4. – P. 231-238.139.Qin J.-Z., Chaturvedi V., Denning M.F. et al. Pegulation of apoptosisby p53 in UV-irradiated human epidermis, psoriatic plaques and senescentkeratinocytes. // Oncogene. 2002. - V.21. - P.2991-3002.140.Rath N., Kar H.K., Sabhnani S.
An open labeled, comparative clinicalstudy on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMPwith PUVA and broad / narrow band UVB phototherapy in progressive vitiligo.//Indian J Dermatol Venereol Leprol. 2008; 74: 357—360141.Reyes E., Jaen P., De Las Heras E., Carrion F., De Eusebio E., AlvareM., Cuevas J., González S., Villarrubia V.G. Systemic immunomodulatory effectsof Polypodium leucotomos as an adjuvant to PUVA therapy in generalized vitiligo:A pilot study. Journal of Dermatological Science. 2006; 41(3): 213—216.;112142.Rezaei N., Gavalas N.G., Weetman A.P., Kemp E.H. Autoimmunityas an aetiological factor in vitiligo.//J Eur Acad Dermatol Venereol.
2007Aug;21(7):865-76143.Rodrigue-Gervais I.G., Saleh M. Genetics of inflammasome-associated disorders: a lesson in the guiding principals of inflammasomefunction.//Eur J Immunol. 2010 Mar;40(3):643-8144.Ruiz-Argüelles A., Brito G.J., Reyes-Izquierdo P., Pérez-Romano B.,Sánchez-SosaS.Apoptosisofmelanocytesinvitiligoresultsfromantibodypenetration.J Autoimmun. 2007 Dec;29(4):281-6. Review145.Schallreuter K.U., Bahadoran P., Picardo M., Slominski A., ElassiutyY.E., Kemp E.H. et al. Vitiligo pathogenesis: autoimmune disease, genetic defect,excessive reactive oxygen species, calcium imbalance, or what else? Controversiesin Experimental Dermatology, Exp. Dermatology 2008; 17 (2): 139—140.146.Schallreuter K.U., Chavan B., Rokos H., Hibberts N., Panske A.,Wood J.M.
Decreased phenylalanine uptake and turnover in patients with vitiligo.//Mol Genet Metab. 2005 Dec;86 Suppl 1:S27-33. Epub 2005 Sep 6.147.Schallreuter K.U., Gibbons NC, Zothner C, Abou Elloof MM, WoodJM Hydrogen peroxide-mediated oxidative stress disrupts calcium binding oncalmodulin: more evidence for oxidative stress in vitiligo.// Biochem Biophys ResCommun. 2007 Aug 17;360(1):70-5. Epub 2007 Jun 11.148.Schallreuter K.U., Krueger C, Wuerfel B., Panske A., Wood JM.From basic research to the bedside: efficacy of topical treatment withpseudocatalase PC-KUS in 71 children with vitiligo. // Int J Dermatol.
2008Jul;47(7):743-53. doi: 10.1111/j.1365-4632.2008.03660.x.150.Schallreuter K.U., Lemke K.R., Brandt O. et al. Vitiligo and otherdiseases: coexistence or true association? Hamburg study on 321 patients. //Dermatology. 1994. - V.l88. - P.269-275.151.Scherschun L., Kim J.J., Lim H.W. Narrow-band ultraviolet B is auseful and well-tolerated treatment for vitiligo.// J Am Acad Dermatol. 2001Jun;44(6):999-1003.113152.Sehgal V.N., Srivastava G. Vitiligo: compendium of clinic-epidemiological features // Indian J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
